Cargando…

Use of anti-TNFs for difficult-to-treat urticaria: response to Cooke et al

Detalles Bibliográficos
Autores principales:	Thomsen, Simon Francis, Sand, Freja Lærke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642805/ https://www.ncbi.nlm.nih.gov/pubmed/26604679 http://dx.doi.org/10.2147/BTT.S98040

Ejemplares similares

TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients
por: Sand, Freja Lærke, et al.
Publicado: (2013)

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
por: Roda, Giulia, et al.
Publicado: (2016)

Clinician's Update on the Benign, Premalignant, and Malignant Skin Tumours of the Vulva: The Dermatologist's View
por: Sand, Freja Lærke, et al.
Publicado: (2017)

Dermatological Diseases Associated with Pregnancy: Pemphigoid Gestationis, Polymorphic Eruption of Pregnancy, Intrahepatic Cholestasis of Pregnancy, and Atopic Eruption of Pregnancy
por: Sävervall, Christine, et al.
Publicado: (2015)

Pemphigoid gestationis: current perspectives
por: Sävervall, Christine, et al.
Publicado: (2017)

Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
por: Roda, Giulia, et al.
Publicado: (2019)

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease
por: Prieto-Pérez, Rocío, et al.
Publicado: (2016)

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
por: Ivyanskiy, Ilya, et al.
Publicado: (2012)

When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?
por: Jansen, Tim L
Publicado: (2010)

MANAGEMENT OF DIFFICULT URTICARIA
por: Yadav, Sudha, et al.
Publicado: (2009)

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review
por: Johansen, Cæcilie Bachdal, et al.
Publicado: (2018)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

PReS-FINAL-2250: Presentation of tuberculosis in patients using anti-TNFS drugs: report of 3 cases
por: Bica, BE, et al.
Publicado: (2013)

Use of non-TNF biologics for the treatment of neuro-Behçet's disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab
por: Karabulut, Yusuf
Publicado: (2022)

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
por: Taylor, Peter C., et al.
Publicado: (2023)

Response to Sadek et al. and Kotlikoff et al.
por: Andersen, Ditte Caroline, et al.
Publicado: (2014)

Prevalence, predictors, and clinical relevance of α‐gal sensitization in patients with chronic urticaria
por: Pedersen, Helena Swee‐Lin Trige, et al.
Publicado: (2022)

Dupilumab as a novel therapy to treat adrenergic urticaria
por: Goodman, Brian, et al.
Publicado: (2021)

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays
por: Fossati, G, et al.
Publicado: (2010)

Urticaria in Monozygotic and Dizygotic Twins
por: Thomsen, Simon Francis, et al.
Publicado: (2012)

Response to letters by Baethge et al. and Martino et al.
por: Marwaha, Steven, et al.
Publicado: (2017)

Response to the Critics by Pekkanen et al
por: Hyvönen, Saija, et al.
Publicado: (2020)

Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
por: Pedersen, Nadja Højgaard, et al.
Publicado: (2023)

Response to Belgard et al.
por: Skafidas, E, et al.
Publicado: (2014)

Response to Miner et al.
por: Currie, Mark G, et al.
Publicado: (2017)

Response to Simon et al.,
por: Wei, Wei, et al.
Publicado: (2017)

Response to Higashi et al.
por: Moriwaki, Kuniaki, et al.
Publicado: (2019)

Response to Alvarez et al.
por: Coste, Joël, et al.
Publicado: (2021)

Response to Krishnasamy et al
por: Morello, William, et al.
Publicado: (2022)

Response to Fullarton et al
por: Kieffer, Alexia, et al.
Publicado: (2022)

Response to letter from Verdura et al
por: Lear, William
Publicado: (2021)

Response to the Letter to the Editor by Eberhard et al.
por: Bottomley, Christian, et al.
Publicado: (2017)

A response to Al et al. Trials 2023;24:233
por: Merz, Jon F.
Publicado: (2023)

Yellow Urticaria
por: Kränke, Teresa, et al.
Publicado: (2022)

Response to Kounali et al.'s letter of response
por: White, P. J., et al.
Publicado: (2019)

Response to Morrell et al's reply
por: Miller, Anthony B
Publicado: (2017)

Response to paper by Tsioufis et al.
por: Liebert, Casril, et al.
Publicado: (2020)

Response to Bowsher et al. (2021) veterinary intelligence
por: Fraser, Mary, et al.
Publicado: (2021)

Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data
por: Zhuleku, Evi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sb2ao43j6r48pj9k8s3tiv670d